EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multiple Veterans Affairs Medical Centers.

Trial Details

NCT ID
NCT05467748
Phase
PHASE1 / PHASE2
Sponsor
VA Office of Research and Development
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Tulmimetostat
Locations (sample)
  • Long Beach, California, United States|33.76696,-118.18923
  • Sacramento, California, United States|38.58157,-121.4944
  • San Diego, California, United States|32.71571,-117.16472
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Provide written informed consent/assent for the trial. The trial consent includes future biomedical research.
  • Male/female participants who are at least 18 years of age on the day of signing informed consent
  • Patients with histologically confirmed diagnosis of advanced non-small cell lung cancer.
  • Have a life expectancy of 12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →